Digital Content

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. We’ll assume you’re ok with this, but you can opt out if you wish. See our 

Footer

Column Name Goes Here

Footer V2

2024 Event

Event Global

New HLTH Insights Programs

Become a Hosted Buyer

Become a Sponsor/Exhibitor

Apply for Media Pass

Promote Your Presence

2023 Event

Event Global Footer

Startup Opportunities

Hotel

2022 Event

LLC Global

2021 Event

LLC Menu Official

LLC Menu

The Rise of Weight Loss Medications: A Healthcare Trend

Healthcare is complicated, and most people don’t think about it until they need it. In this podcast episode, Saul Marquez welcomes Dr. James Wantuck, the Associate Chief Medical Officer at Accolade, who begins by stating his motivation for entering the healthcare field—a desire to have a significant impact on people&#39;s lives. James delves into the rising popularity of weight management medications, particularly GLP-1s, and the challenges employers face in providing coverage. James shares the results of an extensive survey conducted by Accolade, highlighting the demand for these medications and their potential as a recruitment and retention tool for employees. Finally, Dr. Wantuck emphasizes the importance of the doctor-patient relationship in designing individualized weight management programs and addresses the current medication shortage. Tune in to this discussion to discover the future of weight management and personalized healthcare and how Accolade and PlushCare contribute to this evolving landscape. About James Wantuck:James Wantuck is the Associate Chief Medical Officer at Accolade, where he manages a large, growing group of physicians, therapists, and clinical operations staff while working with patients daily. He&#39;s a board-certified internal medicine physician who co-founded PlushCare in 2015 and grew it to over 200 physicians offering high-quality, accessible, direct-to-consumer virtual care. James earned his Bachelor of Science degree in Chemistry and Neuroscience from the University of Pittsburgh and then earned his doctorate in Medicine at the Vanderbilt University School of Medicine. His mission is to help people at scale. Things You’ll Learn:<ul><li>There is a rising popularity of weight management medication in healthcare.</li><li>GLP-1s are driving the trend when it comes to weight management medications. They are not magic, though.</li><li>Healthcare is complicated, and most people don’t think about it until they need it.</li><li>Hiring a physician with entrepreneurial skills can greatly benefit a healthcare organization.</li><li>Staying responsive to market changes is essential for helping patients access better care.</li></ul>Resources:<ul><li>Connect with and follow James Wantuck on <a href="https://www.linkedin.com/in/jameswantuck/" target="_blank">LinkedIn</a>.</li><li>Follow Accolade on <a href="https://www.linkedin.com/company/accolade-inc-/" target="_blank">LinkedIn</a> and visit their <a href="https://www.accolade.com/?utm_source=linkedin&amp;utm_medium=hero_url" target="_blank">website</a>.</li><li>Learn more about PlushCare on their <a href="https://plushcare.com/" target="_blank">website</a> and follow them on <a href="https://www.linkedin.com/company/plushcare/" target="_blank">LinkedIn</a>.</li><li>The Accolade App has over 17,000 positive reviews. Download it <a href="https://apps.apple.com/us/app/accolade-inc/id1203452254" target="_blank">here</a>.</li></ul>

S4 E10: The Rise of Weight Loss Medications: A Healthcare Trend

Associate Chief Medical Officer

The Beat: Sanofi's Pattern Recognition in Vaccine Development

The vaccine business is highly competitive. But Sanofi stands out particularly well. In this episode, Deborah Glasser, Sanofi’s Head of Vaccines for North America, delves into Sanofi&#39;s extensive history in the vaccine business, focusing on areas such as influenza, neurology, and rare diseases. Deborah provides a glimpse into the groundbreaking RSV monoclonal antibody, Beyfortus, designed to protect infants from the leading cause of hospitalizations. She emphasizes the unique approach of using a monoclonal antibody for newborns, highlighting its potential to revolutionize RSV prevention. Deborah also touches on Sanofi&#39;s efforts in flu prevention, such as consumer education and the importance of immunization, especially for the vulnerable population aged 65 and older. She sheds light on Sanofi&#39;s innovative use of Artificial Intelligence (AI) in both drug discovery and commercial practices and shares Sanofi&#39;s interest in collaborating with startups, particularly those aligned with health system goals. Tune in and learn how Sanofi&#39;s dedication to science and technology shapes the landscape of vaccine development and public health. About Deborah Glasser:Deborah Glasser holds an MBA in Marketing and Finance from the University of Chicago Booth School of Business and a B.A. with honors from Tufts University. Deborah is currently the Head of Vaccines in North America at Sanofi. In this role, she spearheads a team committed to pursuing scientific breakthroughs, focusing on the development and enhancement of immunizations. Sanofi, a global pharmaceutical giant, places a strong emphasis on innovation, and Deborah plays a crucial role in driving the vision forward, expanding access to vaccines, and advancing public health initiatives throughout the U.S. and Canada. Drawing on a rich and varied professional background, Deborah brings more than a decade of experience to her current role. Her journey includes an illustrious 13-year tenure at Biogen, where she held diverse positions across its U.S., European, and global organizations. Notably, she played a key role in the successful launch of Tecfidera, an oral multiple sclerosis product that achieved remarkable success, generating $1.3 billion in U.S. sales within its first four full quarters on the market. Things You’ll Learn:<ul><li>The vaccine industry faces intense competition.</li><li>RSV stands as the primary reason for infant hospitalizations.</li><li>Approximately 70 out of every 100,000 individuals end up hospitalized due to the flu.</li><li>The flu poses a significant and serious risk, with an average of 36,000 deaths annually, potentially reaching 98,000 in severe seasons. These deaths are preventable.</li><li>It&#39;s crucial to recognize the seriousness of the flu and take preventive measures to avoid unnecessary fatalities.</li></ul> Resources:<ul><li>Connect with and follow Deborah Glasser on <a href="https://www.linkedin.com/in/deborah-glasser-b06643/" target="_blank">LinkedIn</a>.</li><li>Follow Sanofi on <a href="https://www.linkedin.com/company/sanofi/" target="_blank">LinkedIn</a> and visit their <a href="https://www.sanofi.com/en" target="_blank">website</a>.</li></ul>

S1 E6: The Beat: Sanofi's Pattern Recognition in Vaccine Development

Head of Vaccines, North America

The Beat: The Mystery of Obesity

Research says 40% of adults and 20% of children have obesity. The US obesity treatment market is about $15 billion. The US weight loss market is about 160 billion. In this episode, the show welcomes Dr. Rekha Kumar, the Chief Medical Officer of Found, a digital health company focused on treating obesity. Dr. Kumar explains Found&#39;s unique approach, combining behavioral interventions with telehealth services to provide a comprehensive solution for patients struggling with obesity. She delves into the complexity of obesity as a heterogeneous disease, emphasizing the need for personalized care. Rekha also sheds light on the challenges in the obesity treatment market, where various options, from lifestyle changes to medications like GLP-1s, create confusion for consumers. She clarifies that there is no one-size-fits-all solution, and Found&#39;s clinical rigor and personalized approach set it apart. Finally, Rekha proudly shares impressive outcomes, with 90% of patients achieving a 10% body weight loss in one year. For insights into the science of obesity, personalized care, and the impact of Found&#39;s innovative approach, tune in and learn how this digital health company is revolutionizing weight loss! About Rekha Kumar:Dr. Rekha Kumar is a globally recognized leader in the field of Obesity Medicine, currently holding the position of Chief Medical Officer at Found, a weight care platform. With a past role as the medical director of the American Board of Obesity Medicine, Dr. Kumar has shared her insights on the international stage regarding the medical evaluation and treatment of obesity.  Contributing significantly to her field, she has authored various papers and textbook chapters and serves as an Associate Editor for the Obesity Journal. Her expertise extends to diverse topics, including the clinical assessment of patients with obesity and metabolic syndrome, the impact of obesity on reproductive health and fertility, and thyroid disease.  Dr. Kumar&#39;s educational journey took her from Duke University for her undergraduate studies to receiving her M.D. from New York Medical College. She further honed her skills through residency training in Internal Medicine at the New York Presbyterian Hospital/Weill-Cornell Medical College. Beyond her clinical work, Dr. Kumar has actively participated in global health initiatives, exploring the landscape of metabolic diseases in countries like India, China, and Tanzania. She is a valued member of the board of advisors for the Duke Global Health Institute and holds Board Certifications in Internal Medicine, Endocrinology, Diabetes, &amp; Metabolism, and Obesity Medicine. <a href="https://www.conference-board.org/bio/rekha-kumar" target="_blank">Source</a> Things You’ll Learn:<ul><li>Obesity is a heterogeneous disease. What works for one person may not work for another. </li><li>Found&#39;s outcomes boast a 90% success rate, with patients achieving a 10% body weight loss in one year.</li><li>Research says 40% of adults and 20% of children have obesity. The US obesity treatment market is about $15 billion. The US weight loss market is about 160 billion.</li><li>There’s a biological component to obesity; it’s not just willpower, diet, and exercise.</li><li>The root cause of each person’s weight gain can be vastly different.</li></ul>Resources:<ul><li>Connect with and follow Rekha Kumar on <a href="https://www.linkedin.com/in/rekha-kumar-m-d-m-s-70b481237/" target="_blank">LinkedIn</a>.</li><li>Follow Found on <a href="https://www.linkedin.com/company/joinfoundhealth/" target="_blank">LinkedIn</a> and visit their <a href="https://joinfound.com/" target="_blank">website</a>.</li></ul>

S1 E7: The Beat: The Mystery of Obesity

Chief Medical Officer

Prenuvo: The Pioneer in Whole-Body MRI Screenings—featuring Andrew Lacy

The current healthcare system is a reactive one. We only see a doctor when something is wrong, and disease is rarely diagnosed in its early stages. But Andrew Lacy is working to make our sick care system much more proactive. Andrew is Founder and CEO of <a href="https://www.prenuvo.com/" target="_blank">Prenuvo</a>, the pioneer in MRI-based, clinical-diagnostic screening exams. Under his leadership, the company has expanded across North America, establishing Prenuvo as a recognized and trusted proactive healthcare service. On this episode of HLTH Matters, Andrew joins hosts Dr. Jessica Shepherd and Dr. Gautam Gulati to discuss the future of whole-body imaging diagnostics for early disease detection and prevention. Andrew explains what differentiates Prenuvo from the typical healthcare experience and how his technology differs from other MRI options.  Listen in for Andrew’s insight on empowering people with a roadmap of what’s going on in their body and learn how Prenuvo inspires the lifestyle changes that have a massive impact on patient health.  Topics Covered<ul><li>How Andrew’s own health crisis inspired him to build Prenuvo</li><li>How Prenuvo’s whole-body screening empowers patients with information about their health</li><li>What differentiates Prenuvo from the typical healthcare experience</li><li>Why there’s a growing acceptance of the technology for full-body imaging</li><li>How Andrew responds to the 2 most common objections to Prenuvo—unnecessary follow-up and worry</li><li>What distinguishes the Prenuvo technology from other MRI options</li><li>The challenge around training radiologists to be comfortable with a whole-body approach</li><li>The 3 most typical profiles of a Prenuvo patient and who it ISN’T for</li><li>The top features of Prenuvo from a women’s health perspective</li><li>When a Prenuvo scan is covered by insurance (and when it isn’t)</li><li>How Prenuvo imaging inspires clients to make important lifestyle changes</li><li>How Prenuvo is training AI to identify subtle signals of early disease</li></ul> Connect with Andrew Lacy<ul><li><a href="https://www.prenuvo.com/" target="_blank">Prenuvo</a></li></ul> Connect with Dr. Jessica Shepherd &amp; Dr. Gautam Gulati<ul><li><a href="https://www.hlth.com/" target="_blank">HLTH</a></li><li>Dr. Shepherd on <a href="https://twitter.com/JShepherd_MD" target="_blank">X</a></li><li>Dr. Shepherd on <a href="https://www.linkedin.com/in/jessica-shepherd-md-mba-5ba9ab66/" target="_blank">LinkedIn</a></li><li>Dr. Gulati on <a href="https://twitter.com/drgautamgulati" target="_blank">X</a></li><li>Dr. Gulati on <a href="https://www.linkedin.com/in/gautamgulati/" target="_blank">LinkedIn</a></li></ul> Resources<ul><li><a href="https://nikohealth.com/" target="_blank">NikoHealth</a></li></ul>

S4 E17: Prenuvo: The Pioneer in Whole-Body MRI Screenings—featuring Andrew Lacy

Founder and CEO

Podcast

S4 E10: The Rise of Weight Loss Medications: A Healthcare Trend

FEATURING